Skip to content

Advertisement

Articles

Sort by
Page 1 of 63
  1. Content type: Position article and guidelines

    Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy – characterized by some benefi...

    Authors: Julie R. Brahmer, Ramaswamy Govindan, Robert A. Anders, Scott J. Antonia, Sarah Sagorsky, Marianne J. Davies, Steven M. Dubinett, Andrea Ferris, Leena Gandhi, Edward B. Garon, Matthew D. Hellmann, Fred R. Hirsch, Shakuntala Malik, Joel W. Neal, Vassiliki A. Papadimitrakopoulou, David L. Rimm…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:75

    Published on:

  2. Content type: Research article

    Previous studies have suggested that elevated neutrophil-to-lymphocyte ratio (NLR) is prognostic for worse outcomes in patients with a variety of solid cancers, including those treated with immune checkpoint i...

    Authors: Mariaelena Capone, Diana Giannarelli, Domenico Mallardo, Gabriele Madonna, Lucia Festino, Antonio Maria Grimaldi, Vito Vanella, Ester Simeone, Miriam Paone, Giuseppe Palmieri, Ernesta Cavalcanti, Corrado Caracò and Paolo Antonio Ascierto

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:74

    Published on:

  3. Content type: Case report

    Use of anti-programmed cell death-1 (anti-PD-1) has been successful in treating many types of cancers. Despite its promising efficacy, immune-related adverse events are still a major concern. Immune-related ca...

    Authors: Chien-Yi Hsu, Yu-Wen Su and San-Chi Chen

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:72

    Published on:

  4. Content type: Case report

    Treatment of metastatic melanoma patients with immune checkpoint inhibitors is an important standard of care. Side effects are due to immune activation, can affect virtually all organ systems, and are occasion...

    Authors: Andrew Hantel, Brooke Gabster, Jason X. Cheng, Harvey Golomb and Thomas F. Gajewski

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:73

    Published on:

  5. Content type: Research article

    Mutation-derived neoantigens represent an important class of tumour-specific, tumour rejection antigens, and are attractive targets for TCR gene therapy of cancer. The majority of such mutations are patient-sp...

    Authors: Vanessa M. Tubb, Deborah S. Schrikkema, Nathan P. Croft, Anthony W. Purcell, Carsten Linnemann, Manon R. Freriks, Frederick Chen, Heather M. Long, Steven P. Lee and Gavin M. Bendle

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:70

    Published on:

  6. Content type: Short report

    Adoptive transfer of T cells transduced with Chimeric Antigen Receptors (CAR) are now FDA-approved for the treatment of B-cell malignancies. Yet, the functionality of the endogenous TCR in CART cells has not b...

    Authors: Benjamin O. Tschumi, Nina Dumauthioz, Bastien Marti, Lianjun Zhang, Pascal Schneider, Jean-Pierre Mach, Pedro Romero and Alena Donda

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:71

    Published on:

  7. Content type: Research article

    Anaplastic thyroid carcinoma (ATC) is a rare but deadly form of thyroid cancer. Kinase inhibitors kinase inhibitors have shown clinical efficacy in the management of ATC, however, eventually these tumors acqui...

    Authors: Priyanka C. Iyer, Ramona Dadu, Maria Gule-Monroe, Naifa L. Busaidy, Renata Ferrarotto, Mouhammed Amir Habra, Mark Zafereo, Michelle D. Williams, G. Brandon Gunn, Horiana Grosu, Heath D. Skinner, Erich M. Sturgis, Neil Gross and Maria E. Cabanillas

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:68

    Published on:

  8. Content type: Review

    Immunotherapy represents the third important wave in the history of the systemic treatment of cancer after chemotherapy and targeted therapy and is now established as a potent and effective treatment option ac...

    Authors: Paolo A. Ascierto, James Brugarolas, Luigi Buonaguro, Lisa H. Butterfield, David Carbone, Bruno Daniele, Robert Ferris, Bernard A. Fox, Jérôme Galon, Cesare Gridelli, Howard L. Kaufman, Christopher A. Klebanoff, Ignacio Melero, Paul Nathan, Chrystal M. Paulos, Marco Ruella…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:69

    Published on:

  9. Content type: Case report

    Immune checkpoint inhibitors (CPIs) have shown promising results in many solid tumors. There are limited data on the safety and efficacy of these drugs in HIV infected patients as they have traditionally been ...

    Authors: Muhammad Husnain, Wungki Park, Juan Carlos Ramos, Thomas E. Johnson, Joseph Chan, Arvind Dasari, Raja Mudad and Peter J. Hosein

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:66

    Published on:

  10. Content type: Review

    Recent advances in our understanding of the dynamics of cellular cross-talk have highlighted the significance of host-versus-tumor effect that can be harnessed with immune therapies. Tumors exploit immune chec...

    Authors: Muhammad Umair Mushtaq, Athanasios Papadas, Adam Pagenkopf, Evan Flietner, Zachary Morrow, Sibgha Gull Chaudhary and Fotis Asimakopoulos

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:65

    Published on:

  11. Content type: Research article

    Metformin is one of the biguanides commonly used in patients with type II Diabetes Mellitus. Apart from its hypoglycemic properties, metformin also inhibits the cell cycle by restricting protein synthesis and ...

    Authors: Muhammad Zubair Afzal, Rima R. Mercado and Keisuke Shirai

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:64

    Published on:

  12. Content type: Research article

    The Tumor Inflammation Signature (TIS) is an investigational use only (IUO) 18-gene signature that measures a pre-existing but suppressed adaptive immune response within tumors. The TIS has been shown to enric...

    Authors: Patrick Danaher, Sarah Warren, Rongze Lu, Josue Samayoa, Amy Sullivan, Irena Pekker, Brett Wallden, Francesco M. Marincola and Alessandra Cesano

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:63

    Published on:

  13. Content type: Research article

    Natural killer (NK) cells recognize and lyse target tumor cells in an MHC-unrestricted fashion and complement antigen- and MHC-restricted killing by T-lymphocytes. NK cells and T-lymphocytes mediate early kill...

    Authors: Jay Friedman, Megan Morisada, Lillian Sun, Ellen C. Moore, Michelle Padget, James W. Hodge, Jeffrey Schlom, Sofia R. Gameiro and Clint T. Allen

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:59

    Published on:

  14. Content type: Research article

    Indoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible for acquired immune tolerance associated with cancer. The IDO1 small molecule inhibitor n...

    Authors: Asha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, Robin Dobbins, Lisa Marshall, Nicholas N. Vahanian, W. Jay Ramsey, Eugene Kennedy, Mario R. Mautino, Charles J. Link, Ray S. Lin, Stephanie Royer-Joo, Xiaorong Liang, Laurent Salphati, Kari M. Morrissey, Sami Mahrus…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:61

    Published on:

  15. Content type: Short report

    Antiviral responses are barriers that must be overcome for efficacy of oncolytic virotherapy. In mammalian cells, antiviral responses involve the interferon pathway, a protein-signaling cascade that alerts the...

    Authors: Donald Bastin, Amelia S. Aitken, Adrian Pelin, Larissa A. Pikor, Mathieu J. F. Crupi, Michael S. Huh, Marie-Claude Bourgeois-Daigneault, John C. Bell and Carolina S. Ilkow

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:62

    Published on:

  16. Content type: Case report

    Sebaceous carcinoma is an aggressive adnexal skin tumor with a predilection for the eyelids and sebaceous glands of the head and neck.

    Authors: Evidio Domingo-Musibay, Paari Murugan, Alessio Giubellino, Sandeep Sharma, Daniel Steinberger, Jianling Yuan, Matthew A. Hunt, Emil Lou and Jeffrey S. Miller

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:58

    Published on:

  17. Content type: Review article

    Immune checkpoint antagonists (CTLA-4 and PD-1/PD-L1) and CAR T-cell therapies generate unparalleled durable responses in several cancers and have firmly established immunotherapy as a new pillar of cancer the...

    Authors: Robert D. Leone and Leisha A. Emens

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:57

    Published on:

  18. Content type: Review

    During the last decade the field of cancer immunotherapy has witnessed impressive progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T-cell engaging therapies like bispecific ...

    Authors: Alexander Shimabukuro-Vornhagen, Philipp Gödel, Marion Subklewe, Hans Joachim Stemmler, Hans Anton Schlößer, Max Schlaak, Matthias Kochanek, Boris Böll and Michael S. von Bergwelt-Baildon

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:56

    Published on:

  19. Content type: Research article

    Pixatimod (PG545) is a novel clinical-stage immunomodulatory agent capable of inhibiting the infiltration of tumor-associated macrophages (TAMs) yet also stimulate dendritic cells (DCs), leading to activation ...

    Authors: Edward Hammond, Nicole M. Haynes, Carleen Cullinane, Todd V. Brennan, Darryn Bampton, Paul Handley, Tomislav Karoli, Fleur Lanksheer, Liwen Lin, Yiping Yang and Keith Dredge

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:54

    Published on:

  20. Content type: Case report

    The treatment options for metastatic malignant melanoma have drastically changed recently,including the increased use of immunotherapeutic agents that offer significant responses. Accordingly, it hasbecome com...

    Authors: Joseph I. Clark, Shams Bufalino, Shruti Singh and Ewa Borys

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:53

    Published on:

  21. Content type: Research article

    Oncolytic viruses are currently experiencing accelerated development in several laboratories worldwide, with some forty-seven clinical trials currently recruiting. Many oncolytic viruses combine targeted cytot...

    Authors: Janet Lei, Egon J. Jacobus, William K. Taverner, Kerry D. Fisher, Silvio Hemmi, Katy West, Lorna Slater, Fred Lilley, Alice Brown, Brian Champion, Margaret R. Duffy and Len W. Seymour

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:55

    Published on:

  22. Content type: Case report

    Immune checkpoint inhibitors (ICI) target T cell inhibitory pathways that are responsible for cancer tolerance by down-modulating immune functions. ICI have revolutionized patients care with lung cancer. Never...

    Authors: Léa Paolini, Caroline Poli, Simon Blanchard, Thierry Urban, Anne Croué, Marie-Christine Rousselet, Sarah Le Roux, Nathalie Labarrière, Pascale Jeannin and José Hureaux

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:52

    Published on:

  23. Content type: Research article

    Corticosteroids are routinely utilized to alleviate edema in patients with intracranial lesions and are first-line agents to combat immune-related adverse events (irAEs) that arise with immune checkpoint block...

    Authors: Amber J. Giles, Marsha-Kay N. D. Hutchinson, Heather M. Sonnemann, Jinkyu Jung, Peter E. Fecci, Nivedita M. Ratnam, Wei Zhang, Hua Song, Rolanda Bailey, Dionne Davis, Caitlin M. Reid, Deric M. Park and Mark R. Gilbert

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:51

    Published on:

Page 1 of 63

2017 Journal Metrics

Advertisement